October 15th 2024
An analysis of 16 studies showed that CAR T-cell therapy is safe and effective for relapsed/refractory mantle cell lymphoma.
September 6th 2024
Adding Bispecific Antibody to Natural Killer Cells May Be Effective in Heavily Pretreated Lymphoma
April 11th 2022Patients with heavily pretreated lymphoma experienced promising clinical responses following treatment with the innate cell engager AMF13 plus preactivated and expanded natural killers (NK) cells.
NCCN Clinical Practice Guidelines Now Include Duvelisib for Peripheral T-cell Lymphoma
March 17th 2022Duvelisib, a dual PI3K-δ,γ inhibitor, is now listed as a category 2A designated option for second-line and subsequent treatment of patients with relapsed/refractory peripheral T-cell lymphoma in the National Comprehensive Cancer Network Clinical Practice Guidelines.
Liso-Cel Outperforms Standard Therapy in Improving QoL in Relapsed/Refractory LBCL
December 29th 2021A comparative analysis indicated that lisocabtagene maraleucel generated superior quality of life in patients with relapsed/refractory large B-cell lymphoma compared with the current standard of care.
Copanlisib Plus Rituximab May Be ‘Viable Option’ Across Indolent Non-Hodgkin Lymphoma
July 16th 2021More data are needed regarding the duration of response associated with this combination to make it a “mainstream” treatment option for patients, according to an expert from the University of Michigan Rogel Cancer Center.
Assessment Predicts Survival In Elderly Patients with DLBCL
April 2nd 2021A simplified geriatric assessment offers a validated objective tool to assess fitness status and should be considered the new Elderly Prognostic Index standard to predict overall survival in older patients with diffuse large B-cell lymphoma.